News
UNCY
3.550
-2.47%
-0.090
Press Release: Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update
Dow Jones · 2h ago
Weekly Report: what happened at UNCY last week (1109-1113)?
Weekly Report · 4h ago
Weekly Report: what happened at UNCY last week (1102-1106)?
Weekly Report · 11/09 09:34
Weekly Report: what happened at UNCY last week (1026-1030)?
Weekly Report · 11/02 09:34
Unicycive Therapeutics: 95% Upside Priced Against A Wall Of Dilution And Regulatory Risk
Seeking Alpha · 10/31 09:07
UNCY UPCOMING DEADLINE: Levi & Korsinsky Alerts Unicycive Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm
Barchart · 10/30 09:15
Russell 2000 estimated to drop 83 stocks in December rebalance - Stephens
Seeking Alpha · 10/29 19:44
Unicycive Therapeutics Hits a Manufacturing Roadblock: Lawsuit Alleges OLC Approval Risks Were Downplayed
TipRanks · 10/28 17:16
UNCY Deadline: Rosen Law Firm Urges Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Stockholders to Contact the Firm for Information About Their Rights
Barchart · 10/27 15:30
Weekly Report: what happened at UNCY last week (1019-1023)?
Weekly Report · 10/26 09:34
Unicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit
PR Newswire · 10/24 14:27
What's Next for Unicycive Therapeutics, Inc. Shareholders After 39.1% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline
PR Newswire · 10/23 18:10
UNCY Shareholder Alert: Unicycive Therapeutics, Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky
Barchart · 10/23 09:45
Average Analyst Price Target for Unicycive Therapeutics Rises 12.32% to $32.54
NASDAQ · 10/23 09:36
Unicycive Therapeutics: Regulatory Overhang Eases as Oxylanthanum Carbonate Advances; Buy Rating Reiterated with Unchanged $30 Price Target
TipRanks · 10/22 19:55
What Does Unicycive Therapeutics, Inc.'s 39.1% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline
PR Newswire · 10/22 18:40
UNCY UPCOMING DEADLINE: SueWallSt Alerts Unicycive Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm
PR Newswire · 10/22 14:11
Robbins LLP Reminds UNCY Investors of the Pending Lead Plaintiff Deadline in the Unicycive Therapeutics, Inc. Securities Class Action Lawsuit
PR Newswire · 10/22 01:42
What Should Unicycive Therapeutics, Inc. Investors Know After 39.1% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline
PR Newswire · 10/21 18:40
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Unicycive Therapeutics (UNCY)
TipRanks · 10/21 17:20
More
Webull provides a variety of real-time UNCY stock news. You can receive the latest news about Unicycive Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About UNCY
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.